ArticleNeurology and therapy2026

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom.

Erwin De Cock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.